Circuit Upholds Dismissal of Fraud Claims Against Genzyme

A securities fraud action against a pharmaceutical company that sells natural biological drugs failed because the plaintiffs did not "convey a cogent and compelling inference of deceitful intent, or reckless disregard of the truth, on the part of defendants," the U.S. Circuit Court of Appeals for the First Circuit has ruled.

YOUR COMPLIMENTARY 15-DAY LAW.COM TRIAL HAS ENDED.
Subscribe now to continue reading →

To continue reading, upgrade and become a Law.com subscriber.
Get 2 MONTHS FREE when you sign up for a 12 month subscription.